Revenue segments as reported by the company.

Immunology

Hematologic Oncology

Aesthetics

Neuroscience

Eye Care

Women's Health

Other Key Products

All other

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, general and administrative

Research and development

Acquired in-process research and development

Other operating expense

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

AbbVie

AbbVie, Inc. is a research-based biopharmaceutical company, which engages in the development and sale of pharmaceutical products. It focuses on treating conditions such as chronic autoimmune diseases in rheumatology, gastroenterology, and dermatology, oncology, including blood cancers, virology, hepatitis C virus (HCV) and human immunodeficiency virus (HIV), neurological disorders, such as Parkinson's, metabolic, comprising thyroid disease and complications associated with cystic fibrosis, pain associated with endometriosis, and other serious health conditions. The company was founded on October 19, 2011 and is headquartered in North Chicago, IL.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

AbbVie surpasses Q4 earnings forecast, eyes growth amid challenges

AbbVie's strong performance in Q4 2022 exceeded expectations, driven by key products like SKYRIZI and RINVOQ. Despite challenges in revenue and HUMIRA erosion, the company is focused on innovation and growth opportunities. Strategic investments in R&D and BD aim to navigate market dynamics and drive future success.

AbbVie surpasses Q1 expectations, eyes international growth amid challenges

AbbVie's Q1 2023 performance exceeded expectations, driven by key product sales and strong international results. While facing challenges in the U.S. market and inflationary pressures, the company remains confident in its long-term growth prospects and strategic initiatives.

AbbVie surpasses Q2 expectations, eyes revenue growth opportunities

AbbVie's Q2 2023 earnings call highlighted strong financial performance, successful execution in key therapeutic areas, and a promising outlook for revenue growth. Despite challenges like biosimilar competition and market dynamics, the company remains confident in its ability to deliver value and maintain growth.

AbbVie exceeds Q3 expectations, focuses on pipeline growth strategies

AbbVie's strong Q3 performance driven by key products and growth platforms, with positive trial results.
Challenges in aesthetics sales and Medicare drug pricing program offset by long-term growth opportunities.
Confidence in pipeline assets and strategic focus on combination therapies for future growth.
Maintaining strong market positions and investing in transformative therapies for competitive advantage.

AbbVie exceeds Q4 expectations, eyes growth through strategic acquisitions

AbbVie's stellar performance in Q4 2023 showcased strong sales growth, successful pipeline advancements, and strategic acquisitions. While facing challenges such as pricing pressures and safety concerns, the company is well-positioned to capitalize on opportunities in expanding its portfolio and driving growth through innovation and strategic partnerships.

AbbVie exceeds Q1 expectations, raises full-year guidance on strong sales growth

AbbVie's Q1 performance exceeded expectations, with strong sales growth in key products. The company raised full-year guidance and remains confident in maintaining good access for its brands. Challenges in aesthetics sales and inventory management are being addressed for future growth.

AbbVie reports robust Q2 results and raises 2024 guidance

AbbVie's strong Q2 performance, raised guidance, and strategic acquisitions highlight its growth trajectory.
Despite near-term challenges, the company's focus on key growth areas positions it for long-term success.
Investments in innovation and market expansion underscore AbbVie's commitment to sustained growth.
Overall, AbbVie's performance in Q2 2024 reflects a resilient and forward-looking approach to business.

AbbVie reports strong Q3 performance, raises guidance and dividend

AbbVie's Q3 2024 performance showcased robust sales growth, increased dividend, and raised revenue guidance, reflecting financial strength and market leadership.
The company's focus on long-term sustainability through investments, acquisitions, and pipeline advancements highlights a commitment to innovation and growth.
While facing challenges in clinical trial management and market competition, AbbVie remains well-positioned to leverage opportunities in diverse therapeutic areas for future growth.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

NEW YORK--(BUSINESS WIRE)--Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against AbbVie, Inc. ("AbbVie" or the “Company) (NYSE: ABBV) and certain of its officers, on behalf of all persons and entities that purchased, or otherwise acquired AbbVie securities between April 30, 2021, and August 31, 2021, (the “Class Period”). Such investors are encouraged to join this case by visiting the firm's site: www.bgandg.com/abbv.

Bronstein, Gewirtz & Grossman, LLC Notifies AbbVie, Inc. (ABBV) Investors of Class Action and Encourages Investors to Contact the Firm

-          Navitoclax is being studied in myelofibrosis, a rare, difficult-to-treat blood cancer -          Results are from an exploratory analysis of 34 myelofibrosis patients who received at least one dose of navitoclax in combination with ruxolitinib after suboptimal response or disease progression with ruxolitinib monotherapy -          Median overall survival was not reached for patients who had a ≥ 1 grade improvement in bone marrow fibrosis or ≥ 20% variant allele frequency reduction -          At the time of analysis with > 2 year follow up the survival estimate was 100% in patients who had improvements in bone marrow fibrosis or variant allele frequency -          Results were presented at the American Association for Cancer Research annual meeting NORTH CHICAGO, Ill. , April 12, 2022 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced new data from a Phase 2 trial of navitoclax in combination with ruxolitinib in patients with myelofibrosis.

AbbVie Presents Positive Investigational Navitoclax Combination Data in Phase 2 REFINE Study Suggesting Anti-Fibrosis Activity for Patients with Myelofibrosis

Bristol-Myers

Vertex Pharmaceuticals

All three are near 52-week highs, but for how long?

3 Soaring Pharma Stocks -- Can They Keep Climbing?

New York, New York--(Newsfile Corp. - April 11, 2022) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of AbbVie Inc. (NYSE: ABBV) between April 30, 2021 and August 31, 2021, inclusive (the "Class Period"), of the important June 6, 2022 lead plaintiff deadline.SO WHAT: If you purchased AbbVie securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees...

ABBV SHAREHOLDER ALERT: ROSEN, A LONGSTANDING LAW FIRM, Encourages AbbVie Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action - ABBV

AbbVie (ABBV) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Can AbbVie (ABBV) Keep the Earnings Surprise Streak Alive?

The price of AbbVie stock (NYSE: ABBV) reached its all-time high of around $174 yesterday. It is up over 12% in a month, while it rose a stellar 63% over the last twelve months.

Will AbbVie Stock Continue To Make New Highs?

Radnor, Pennsylvania--(Newsfile Corp. - April 10, 2022) - The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) informs investors that the firm has filed a securities class action lawsuit against AbbVie, Inc. (AbbVie) (NYSE: ABBV) on behalf of all persons and entities who purchased or otherwise acquired AbbVie securities between April 30, 2021, and August 31, 2021, inclusive (the "Class Period"). Kessler Topaz is one of the world's foremost advocates in protecting the...

Investor Reminder: Kessler Topaz Meltzer & Check, LLP Reminds Investors of Securities Fraud Class Action Lawsuit Filed Against AbbVie, Inc

AstraZeneca

Pfizer

Their solid underlying businesses and dividends make these stocks more secure than most.

3 Safe Stocks to Buy in an Uncertain Market

AbbVie Top Stock To Own

AmerisourceBergen

Archer-Daniels-Midland Company

Amphastar Pharma

CF Industries Holdings

Chevron

Hershey

Kroger

McKesson

The start of 2022 saw a decline in the stock market. For seasoned investors, this was not unexpected, as corrections in the market are commonplace from January through to March.

10 Stocks That Have Moved Over 20% Since The Indices Lost Over 12%!

SAN DIEGO--(BUSINESS WIRE)---- $ABBV #FDA--AbbVie Inc. (ABBV) Misled Investors Regarding the Efficacy of its Drug Rinvoq

Shareholder Alert: Robbins LLP Informs Investors of Class Action Against AbbVie Inc. (ABBV)

RADNOR, Pa.--(BUSINESS WIRE)--ABBV EQUITY ALERT: Kessler Topaz Meltzer & Check, LLP Files Investor Securities Fraud Class Action Lawsuit against AbbVie, Inc. (ABBV)

ABBV EQUITY ALERT: Kessler Topaz Meltzer & Check, LLP Files Investor Securities Fraud Class Action Lawsuit against AbbVie, Inc. (ABBV)

AbbVie is great for dividend investors, and it's great for people looking for growth in 2022. The company's guidance for 2022 is exciting.

Best Stocks for 2022: Up 20% This Year, AbbVie Is Doing Great

Johnson & Johnson

Both Johnson & Johnson and AbbVie are excellent candidates for our barbell strategy to build an enduring portfolio for earlier retirement.

Johnson & Johnson Vs. AbbVie: Why We Hold AbbVie

RADNOR, Pa. , April 7, 2022 /PRNewswire/ -- The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) informs investors that the firm has filed a securities class action lawsuit in the United States District Court for the Northern District of Illinois against AbbVie, Inc. (AbbVie) (NYSE: ABBV) on behalf of all persons and entities who purchased or otherwise acquired AbbVie securities between April 30, 2021, and August 31, 2021, inclusive (the "Class Period").

Kessler Topaz Meltzer & Check, LLP Files Investor Securities Fraud Class Action Lawsuit Against AbbVie, Inc. (ABBV)

Vici Properties

Investors might want to remain in stocks in order to beat 8% inflation, while adding strong dividend yields that top U.S. Treasuries. Here are few stocks to consider buying to do just that.

2 Great Dividend Stocks to Buy Now to Help Tackle Inflation

Did you lose money on investments in AbbVie? If so, please visit AbbVie Inc. Shareholder Class Action Lawsuit or contact  Peter Allocco at (212) 951-2030 or pallocco@bernlieb.com to discuss your rights.

ABBVIE INC. (NYSE: ABBV) SHAREHOLDER CLASS ACTION ALERT: Bernstein Liebhard LLP Announces that a Securities Class Action Lawsuit Has Been Filed Against AbbVie Inc. (NYSE: ABBV)

New York, New York--(Newsfile Corp. - April 7, 2022) - WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of AbbVie Inc. (NYSE: ABBV) between April 30, 2021 and August 31, 2021, inclusive (the "Class Period"). A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no...

ABBV Investor Alert: ROSEN, Global Investor Counsel, Encourages AbbVie Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action - ABBV

Apple

AGNC Investment

AGNC Investment Corp - FXDFR PRF PERPETUAL USD 25 - Ser D 1/1000th int

AGNC Investment Corp. Deposit Shs Repr 1/1000th Cum Conv Red Pfd Registered Shs Series C

Apollo Investment

Allianz SE

Antero Midstream Partners

Apple Hospitality REIT

Preferred Apartment Communities

Ares Capital

Apollo Commercial Real Estate Finance

Broadcom

Boeing

Alibaba

Bank of America

BASF SE

Bayer AG

Brookfield Renewable Partners

B&G Foods

Brookfield Infrastructure Partners L.P.

Bank of Montreal

The war in Ukraine continues to dominate market movements. I am not selling anything and predominantly focus on adding dividend income via select purchases.

My Dividend Stock Portfolio: March 2022 Update - 101 Holdings And 29 Buys

NEW YORK--(BUSINESS WIRE)--WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of AbbVie Inc. (NYSE: ABBV) between April 30, 2021 and August 31, 2021, inclusive (the “Class Period”). A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than June 6, 2022. SO WHAT: If you purchased AbbVie securities during the Class Period you may be entit

EQUITY NOTICE: ROSEN, A TOP RANKED LAW FIRM, Encourages AbbVie Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action – ABBV

AbbVie's strong stock performance is no fluke, and it's time for investors to notice.

Is AbbVie Still a Buy After Its 50% Run-Up?

A few names that fit that description have been some of the biggest outperformers in the market to start the year, which tells us a lot about what institutions and large investors are interested in buying during an uncertain period for both the economy and the market

2 Biotech Stocks Showing Serious Relative Strength

Equinor

Prologis

Regeneron Pharmaceuticals

Exxon Mobil

It's not too late to buy safe stocks. These seven stocks, all A-rated, are perfect plays for riding out continued volatility in the markets.

7 Safe Stocks to Buy to Guard Against a Recession

VUITY is the first and only eye drop to treat presbyopia, or age-related blurry near vision, in adults and is FDA-approved for once-daily administration In the VIRGO trial evaluating twice-daily administration of VUITY, the primary endpoint of improving near vision without compromising distance vision at Day 14, Hour 9 was met Data from the VIRGO trial will be presented at upcoming medical congresses and serve as the basis for a supplemental U.S. New Drug Application submission in the second quarter of 2022 NORTH CHICAGO, Ill. , April 5, 2022 /PRNewswire/ -- Allergan, an AbbVie (NYSE: ABBV) company, today announced that the Phase 3 VIRGO trial evaluating the safety and efficacy of investigational twice-daily administration of VUITY™ (pilocarpine HCl ophthalmic solution) 1.25% in adults with presbyopia met its primary efficacy endpoint, improving near vision without compromising distance vision at Hour 9 (3 hours after the second drop) on Day 14.

Allergan, an AbbVie Company, Announces Positive Topline Phase 3 Results Evaluating Investigational Twice-Daily Administration of VUITY™ (pilocarpine HCI ophthalmic solution) 1.25% in Adults with Age-Related Blurry Near Vision (Presbyopia)

Teva Pharmaceutical

West Virginia's attorney general urged a judge to hold Johnson & Johnson (NYSE: JNJ), Teva Pharmaceuticals Industries Ltd (NYSE: TEVA), and AbbVie Inc's (NYSE: ABBV) Allergen accountable for causing a "tsunami" of opioid addiction in the.

West Virginia Says J&J, Teva, AbbVie Caused 'Tsunami' Of Opioid Addiction: Reuters

News for AbbVie Stock (ABBV)